ANTI-HYPERGLYCEMIC EFFECTS OF ETHANOLIC EXTRACT OF SYZYGIUM ALTERNIFOLIUM (WIGHT) WALP. IN ALLOXAN INDUCED DIABETES RAT MODELS

The present study carried out as a sequel to our previous report on the rare botanical Syzygium alternifolium (Wight) Walp evaluates medicinal use of the species in the treatment of diabetes. Antidiabetic activity of ethanolic extract of Syzygium alternifolium (EESA) evaluated for hypoglycemic function in Alloxan monohydrate induced diabetic animal model presented data convincing enough to deal with this vexing health issue. In an experiment designed in accordance to the standard procedure with the clearance of animal ethics committee, different pharma clinical parameters were screened to determine the blood glucose levels as per approval norms. Animal groups treated with EESA have a significant influence in keeping the blood glucose level under control comparable to standard drug control group. Anti-glycemic function in the treatment of the tested two doses of extracts were comparable to the standard drug glipizide. Blood glucose level tested by glucose kit (One Touch Ultra) Johnson Johnson based on glucose oxidase method show that Syzygium alternifolium (EESA) prevented the diabetic condition in direct quantitative terms. The concentration of the higher dosage of the fruits fared well prompting a chance to tap ingredients which might help making new drug providing for the search for novel anti-diabetic agents.